Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)] (Journal of Hepatology (2021) 74(4) (907–918), (S0168827820336746), (10.1016/j.jhep.2020.09.030))

Chunxiao Liu; Zhengyu Zha; Chenhao Zhou; Yeh Chen; Weiya Xia; Ying Nai Wang; Heng Huan Lee; Yirui Yin; Meisi Yan; Chiung Wen Chang; Li Chuan Chan; Yufan Qiu; Hui Li; Chia Wei Li; Jung Mao Hsu; Jennifer L. Hsu; Shao Chun Wang; Ning Ren; Mien Chie Hung

doi:10.1016/j.jhep.2022.04.004

Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)] (Journal of Hepatology (2021) 74(4) (907–918), (S0168827820336746), (10.1016/j.jhep.2020.09.030))

Chunxiao Liu, Zhengyu Zha, Chenhao Zhou, Yeh Chen, Weiya Xia, Ying Nai Wang, Heng Huan Lee, Yirui Yin, Meisi Yan, Chiung Wen Chang, Li Chuan Chan, Yufan Qiu, Hui Li, Chia Wei Li, Jung Mao Hsu, Jennifer L. Hsu, Shao Chun Wang, Ning Ren, Mien Chie Hung

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

It has come to our attention that an error was introduced during the production process of this manuscript. The labels for Fig. 5D, ‘+crizotinib’ and ‘-crizotinib’, are inverted in the published version. The corrected panel is included below. We apologise for any inconvenience caused.[Formula

Original language	English (US)
Pages (from-to)	580
Number of pages	1
Journal	Journal of Hepatology
Volume	77
Issue number	2
DOIs	https://doi.org/10.1016/j.jhep.2022.04.004
State	Published - Aug 2022

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.jhep.2022.04.004

Fingerprint

Dive into the research topics of 'Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)] (Journal of Hepatology (2021) 74(4) (907–918), (S0168827820336746), (10.1016/j.jhep.2020.09.030))'. Together they form a unique fingerprint.

Cite this

Liu, C., Zha, Z., Zhou, C., Chen, Y., Xia, W., Wang, Y. N., Lee, H. H., Yin, Y., Yan, M., Chang, C. W., Chan, L. C., Qiu, Y., Li, H., Li, C. W., Hsu, J. M., Hsu, J. L., Wang, S. C., Ren, N., & Hung, M. C. (2022). Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)] (Journal of Hepatology (2021) 74(4) (907–918), (S0168827820336746), (10.1016/j.jhep.2020.09.030)). Journal of Hepatology, 77(2), 580. https://doi.org/10.1016/j.jhep.2022.04.004

Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)] (Journal of Hepatology (2021) 74(4) (907–918), (S0168827820336746), (10.1016/j.jhep.2020.09.030)). / Liu, Chunxiao; Zha, Zhengyu; Zhou, Chenhao et al.
In: Journal of Hepatology, Vol. 77, No. 2, 08.2022, p. 580.

Research output: Contribution to journal › Comment/debate › peer-review

Liu, C, Zha, Z, Zhou, C, Chen, Y, Xia, W, Wang, YN , Lee, HH, Yin, Y, Yan, M, Chang, CW, Chan, LC, Qiu, Y, Li, H, Li, CW, Hsu, JM, Hsu, JL, Wang, SC, Ren, N & Hung, MC 2022, 'Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)] (Journal of Hepatology (2021) 74(4) (907–918), (S0168827820336746), (10.1016/j.jhep.2020.09.030))', Journal of Hepatology, vol. 77, no. 2, pp. 580. https://doi.org/10.1016/j.jhep.2022.04.004

Liu C, Zha Z, Zhou C, Chen Y, Xia W, Wang YN et al. Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)] (Journal of Hepatology (2021) 74(4) (907–918), (S0168827820336746), (10.1016/j.jhep.2020.09.030)). Journal of Hepatology. 2022 Aug;77(2):580. doi: 10.1016/j.jhep.2022.04.004

@article{8f8a0b12b311418d958fb07abba2d063,

title = "Erratum to {\textquoteleft}Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma{\textquoteright} [J Hepatol 2021 (907-918)] (Journal of Hepatology (2021) 74(4) (907–918), (S0168827820336746), (10.1016/j.jhep.2020.09.030))",

abstract = "It has come to our attention that an error was introduced during the production process of this manuscript. The labels for Fig. 5D, {\textquoteleft}+crizotinib{\textquoteright} and {\textquoteleft}-crizotinib{\textquoteright}, are inverted in the published version. The corrected panel is included below. We apologise for any inconvenience caused.[Formula",

author = "Chunxiao Liu and Zhengyu Zha and Chenhao Zhou and Yeh Chen and Weiya Xia and Wang, {Ying Nai} and Lee, {Heng Huan} and Yirui Yin and Meisi Yan and Chang, {Chiung Wen} and Chan, {Li Chuan} and Yufan Qiu and Hui Li and Li, {Chia Wei} and Hsu, {Jung Mao} and Hsu, {Jennifer L.} and Wang, {Shao Chun} and Ning Ren and Hung, {Mien Chie}",

note = "Publisher Copyright: {\textcopyright} 2020 European Association for the Study of the Liver",

year = "2022",

month = aug,

doi = "10.1016/j.jhep.2022.04.004",

language = "English (US)",

volume = "77",

pages = "580",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)] (Journal of Hepatology (2021) 74(4) (907–918), (S0168827820336746), (10.1016/j.jhep.2020.09.030))

AU - Liu, Chunxiao

AU - Zha, Zhengyu

AU - Zhou, Chenhao

AU - Chen, Yeh

AU - Xia, Weiya

AU - Wang, Ying Nai

AU - Lee, Heng Huan

AU - Yin, Yirui

AU - Yan, Meisi

AU - Chang, Chiung Wen

AU - Chan, Li Chuan

AU - Qiu, Yufan

AU - Li, Hui

AU - Li, Chia Wei

AU - Hsu, Jung Mao

AU - Hsu, Jennifer L.

AU - Wang, Shao Chun

AU - Ren, Ning

AU - Hung, Mien Chie

PY - 2022/8

Y1 - 2022/8

N2 - It has come to our attention that an error was introduced during the production process of this manuscript. The labels for Fig. 5D, ‘+crizotinib’ and ‘-crizotinib’, are inverted in the published version. The corrected panel is included below. We apologise for any inconvenience caused.[Formula

AB - It has come to our attention that an error was introduced during the production process of this manuscript. The labels for Fig. 5D, ‘+crizotinib’ and ‘-crizotinib’, are inverted in the published version. The corrected panel is included below. We apologise for any inconvenience caused.[Formula

UR - http://www.scopus.com/inward/record.url?scp=85134580327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134580327&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2022.04.004

DO - 10.1016/j.jhep.2022.04.004

M3 - Comment/debate

C2 - 35489965

AN - SCOPUS:85134580327

SN - 0168-8278

VL - 77

SP - 580

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 2

ER -

Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)] (Journal of Hepatology (2021) 74(4) (907–918), (S0168827820336746), (10.1016/j.jhep.2020.09.030))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this